Gretchen E. Taylor, M.D.

  1. Hospitalist
  2. Internist
  1. Ravi SN, Cheema KP, Taylor GE. 52-Year-Old Woman With Recurrent Unexplained Syncope. Mayo Clin Proc. 2024 Jul; 99 (7):1173-1177 Epub 2024 June 01
    View PubMed
  2. Seaberg PH, Kling JM, Klanderman MC, Mead-Harvey C, Williams KE, Labonte HR, Jain A, Taylor GE, Blair JE. Resident factors associated with American board of internal medicine certification exam failure. Med Educ Online. 2023 Dec; 28 (1):2152162
    View PubMed
  3. Khan SJ, Poole KG, Kling JM, Taylor G. Outpatient Primary Care Practitioner Access: Gender-Based Preferences. Womens Health Rep (New Rochelle). 2022; 3 (1):150-154 Epub 2022 Feb 02
    View PubMed
  4. Davis RG, Taylor GE, Yost KJ, Borah BJ, Girardo M, Poole KG. Patient attitudes regarding team-based care. Physician Leadersh J. 2020 May-Jun; 7(3):42-48.
  5. Taylor G, Karlin N, Halfdanarson TR, Coppola K, Grothey A. Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience. Clin Colorectal Cancer. 2018 Jun; 17 (2):e183-e187 Epub 2017 Nov 21
    View PubMed
  6. Ertz-Archambault N, Kosiorek H, Taylor GE, Kelemen K, Dueck A, Castro J, Marino R, Gauthier S, Finn L, Sproat LZ, Palmer J, Mesa RA, Al-Kali A, Foran J, Tibes R. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol. 2017 Jul 1; 3 (7):936-943
    View PubMed
  7. Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA Jr, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Invest New Drugs. 2013 Apr; 31 (2):345-54 Epub 2012 May 22
    View PubMed
  8. Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol. 2013 Mar 1; 31 (7):886-94 Epub 2013 Jan 22
    View PubMed
  9. Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA, Hidalgo M. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs. 2012 Dec; 30 (6):2391-9 Epub 2012 May 01
    View PubMed
  10. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 2011 Sep 1; 17 (17):5793-800 Epub 2011 July 08
    View PubMed